BIOCON BIOLOGICS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 STUDY OF YESINTEK™ BIOSIMILAR TO USTEKINUMAB FOR CHRONIC PLAQUE PSORIASIS
BIOCON LTD - YESINTEK DEMONSTRATES EQUIVALENT EFFICACY AND SAFETY TO STELARA
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.